New era for monoclonal antibody-based immunotherapy for treating multiple myeloma

At the 20th Congress of the European Hematology Association (EHA), Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, reviews the development of immunotherapy using monoclonal antibodies (mAbs) for the treatment of patients multiple myeloma. He focuses on the basic and clinical aspects of the emerging and promising novel mAbs, daratumumab, which targets CD38, and elotuzumab, which targets signaling lymphocytic activation molecule-F7 (SLAMF7).

Share this video  
11th June 2015